The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

Libtayo was approved by the US Food and Drug ... created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general ...

That’s fantastic for a brand-new drug. Should Regeneron wish ... as Zaltrap has given way to Libtayo, their treatment for metastatic melanoma. Libtayo was originally marketed with Sanofi ...

The drug has been approved under the brand name Ordspono ... in combination with Libtayo for perioperative non-small cell lung cancer, was also initiated. A phase II/III study for fianlimab ...